Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition

Congestive Heart Failure

Volumn 18, Issue 3, 2012, Pages 179-182

  Harzand, Arash ^a   Tamariz, Leonardo ^b   Hare, Joshua M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIPURINOL; REACTIVE OXYGEN METABOLITE; URIC ACID; XANTHINE OXIDASE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CORONARY ARTERY BLOOD FLOW; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; MORBIDITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; UPREGULATION; URIC ACID BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ALLOPURINOL; BIOLOGICAL MARKERS; ENZYME INHIBITORS; HEART FAILURE; HUMANS; HYPERURICEMIA; URIC ACID; XANTHINE OXIDASE;

EID: 84861189813     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00262.x     Document Type: Review

References (48)

1. Hare JM, Johnson RJ. UA predicts clinical outcomes in HF: insights regarding the role of XO and UA in disease pathophysiology. Circulation. 2003;107:1951-1953.
2. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
3. Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78-84.
4. Anker SD, Doehner W, Rauchhaus M, et al. UA and survival in chronic heart: failure validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
5. Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum UA after acute myocardial infarction (the Japanese Acute Coronary Syndrome study). Am J Cardiol. 2005;96:489-495.
6. Nieto FJ, Iribarren C, Gross MD, et al. UA and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131-139.
7. Baldus S, Köster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005;39:1184-1190.
8. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum UA with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:1-9.
9. Culleton BF, Larson MG, Kannel WB, Levy D. Serum UA and risk for cardiovascular disease and death: the Framingham Heart study. Ann Intern Med. 1999;131:7-13.
10. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum UA and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-150.
11. Liese AD, Hense H, Löwel H, et al. Association of serum UA with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology. 1999;10:391-397.
12. Bos MJ, Koudstaal PJ, Hofman A, et al. UA is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503-1507.
13. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of XO inhibition upon ejection fraction in HF patients: La Plata study. J Card Fail. 2006;12:491-498.
14. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic HF. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-2309.
15. Leyva F, Anker SD, Godsland IF, et al. UA in chronic HF: a marker of chronic inflammation. Eur Heart J. 1998;19:1814-1822.
16. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left HF. Eur Respir J. 1999;13:682-685.
17. Leyva F, Anker S, Swan JW, et al. Serum UA as an index of impaired oxidative metabolism in chronic HF. Eur Heart J. 1997;18:858-865.
18. Niizeki T, Takeishi Y, Arimoto T, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic HF. J Cardiol. 2006;47:219-228.
19. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of UA, partly secreted from the failing heart, is a prognostic marker in patients with congestive HF. Circ J. 2006;70:1006-1011.
20. Jankowska EA, Ponikowska B, Majda J, et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic HF. Int J Cardiol. 2007;115:151-155.
21. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute HF patients. Euro J Heart Fail. 2007;9:518-524.
22. Alimonda AL, Núñez J, Núñez E, et al. Hyperuricemia in acute HF. More than a simple spectator? Eur J Intern Med. 2009;20:74-79.
23. Tamariz L, Harzand A, Palacio A, et al. UA as a predictor of all-cause mortality in HF: a meta-analysis. Congest Heart Fail. 2011;17:25-30.
24. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, UA, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131:1017-1027.
25. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum UA and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens. 2001;19:1209-1215.
26. Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima study. Hypertens Res. 2001;24:531-536.
27. Sundström J, Sullivan L, D'Agostino RB, et al. Relations of serum UA to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005; 45:28-33.
28. Shankar A, Klein R, Klein BEK, Nieto FJ. The association between serum UA level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens. 2006;20:937-945.
29. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247-252.
30. Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275: 457-464.
31. Bulpitt CJ. Serum UA in hypertensive patients. Br Heart J. 1975;37:1210-1215.
32. Kinsey D, Walther R, Sise HS, et al. Incidence of hyperuricemia in 400 hypertensive subjects. Circulation. 1961;24:972-973.
33. Cuspidi C, Valerio C, Sala C, et al. Lack of association between serum UA and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens. 2007;20:678-685.
34. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle HF model: prediction of survival in HF. Circulation. 2006;113:1424-1433.
35. Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with HF. Euro J Heart Fail. 2011;13:528-536.
36. Watanabe S, Kang D-, Feng L, et al. UA, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-360.
37. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation. 2006;114:1531-1544.
38. Stull LB, Leppo MK, Szweda L, et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95:1005-1011.
39. Amado LC, Saliaris AP, Raju SVY, et al. XO inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced HF. J Mol Cell Cardiol. 2005;39:531-536.
40. Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006;98:271-279.
41. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589-606.
42. Doehner W, Schoene N, Rauchhaus M, et al. Effects of XO inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic HF: results from 2 placebo-controlled studies. Circulation. 2002;105:2619-2624.
43. Farquharson CAJ, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic HF. Circulation. 2002;106:221-226.
44. Feig DI, Kang D, Nakagawa T, et al. UA and hypertension. Curr Hypertens Rep. 2006;8:111-115.
45. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-1742.
46. Rao GN, Corson MA, Berk BC. UA stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604-8608.
47. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering UA. Circulation. 2006;114:2508-2516.
48. Ogino K, Kato M, Furuse Y, et al. UA-lowering treatment with benzbromarone in patients with HF a double-blind placebo-controlled crossover preliminary study. Circulation: HF. 2010;3:73-81.